Pharmacoeconomic considerations in the treatment of psoriatic arthritis.

Suppr

超能文献

作者信息

Kavanaugh A

出版信息

Rheumatology (Oxford). 2006 Jul;45(7):790-1. doi: 10.1093/rheumatology/kel153. Epub 2006 May 16.

DOI:10.1093/rheumatology/kel153

PMID:16705044

Abstract

摘要

相似文献

Pharmacoeconomic considerations in the treatment of psoriatic arthritis.

Rheumatology (Oxford). 2006 Jul;45(7):790-1. doi: 10.1093/rheumatology/kel153. Epub 2006 May 16.

Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.

Rheumatology (Oxford). 2006 Aug;45(8):1029-38. doi: 10.1093/rheumatology/kel147. Epub 2006 Jun 16.

Pharmacoeconomic issues in psoriatic arthritis.

J Rheumatol Suppl. 2012 Jul;89:103-5. doi: 10.3899/jrheum.120258.

Psoriatic arthritis: a dermatologist's perspective.

Am J Clin Dermatol. 2010;11 Suppl 1:19-22. doi: 10.2165/1153416-S0-000000000-00000.

Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?

J Fam Pract. 2007 Nov;56(11):933-4, 937.

Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.

Br J Dermatol. 2008 Aug;159(2):322-30. doi: 10.1111/j.1365-2133.2008.08628.x. Epub 2008 May 22.

Psoriatic arthritis: pharmacoeconomic considerations.

Curr Rheumatol Rep. 2009 Aug;11(4):263-9. doi: 10.1007/s11926-009-0037-x.

[Deresinated naphthalan in the treatment of psoriatic arthritis].

Vopr Kurortol Fizioter Lech Fiz Kult. 1994 Jul-Aug(4):13-5.

Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis.

Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S126-31. Epub 2012 Oct 18.

Treatment of psoriatic arthritis.

Rheumatology (Oxford). 2004 Jul;43(7):938-9. doi: 10.1093/rheumatology/keh189.

引用本文的文献

The cost-effectiveness of biopharmaceuticals: a look at the evidence.

MAbs. 2012 Mar-Apr;4(2):281-8. doi: 10.4161/mabs.4.2.18812. Epub 2012 Mar 1.

Psoriatic arthritis: pharmacoeconomic considerations.

Curr Rheumatol Rep. 2009 Aug;11(4):263-9. doi: 10.1007/s11926-009-0037-x.

The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy.

Rheumatology (Oxford). 2008 Nov;47(11):1664-70. doi: 10.1093/rheumatology/ken320. Epub 2008 Aug 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Pharmacoeconomic considerations in the treatment of psoriatic arthritis.

Rheumatology (Oxford). 2006 Jul;45(7):790-1. doi: 10.1093/rheumatology/kel153. Epub 2006 May 16.

Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.

Rheumatology (Oxford). 2006 Aug;45(8):1029-38. doi: 10.1093/rheumatology/kel147. Epub 2006 Jun 16.

Pharmacoeconomic issues in psoriatic arthritis.

J Rheumatol Suppl. 2012 Jul;89:103-5. doi: 10.3899/jrheum.120258.

Psoriatic arthritis: a dermatologist's perspective.

Am J Clin Dermatol. 2010;11 Suppl 1:19-22. doi: 10.2165/1153416-S0-000000000-00000.

Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?

J Fam Pract. 2007 Nov;56(11):933-4, 937.

Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.

Br J Dermatol. 2008 Aug;159(2):322-30. doi: 10.1111/j.1365-2133.2008.08628.x. Epub 2008 May 22.

Psoriatic arthritis: pharmacoeconomic considerations.

Curr Rheumatol Rep. 2009 Aug;11(4):263-9. doi: 10.1007/s11926-009-0037-x.

[Deresinated naphthalan in the treatment of psoriatic arthritis].

Vopr Kurortol Fizioter Lech Fiz Kult. 1994 Jul-Aug(4):13-5.

Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis.

Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S126-31. Epub 2012 Oct 18.

Treatment of psoriatic arthritis.

Rheumatology (Oxford). 2004 Jul;43(7):938-9. doi: 10.1093/rheumatology/keh189.

引用本文的文献

The cost-effectiveness of biopharmaceuticals: a look at the evidence.

MAbs. 2012 Mar-Apr;4(2):281-8. doi: 10.4161/mabs.4.2.18812. Epub 2012 Mar 1.

Psoriatic arthritis: pharmacoeconomic considerations.

Curr Rheumatol Rep. 2009 Aug;11(4):263-9. doi: 10.1007/s11926-009-0037-x.

The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy.

Rheumatology (Oxford). 2008 Nov;47(11):1664-70. doi: 10.1093/rheumatology/ken320. Epub 2008 Aug 24.